Company Overview and News
Designed to provide broad exposure to the Asia-Pacific (Developed) ETFs category of the U.S. equity market, the WisdomTree Japan SmallCap Dividend Fund (DFJ - Free Report) is a smart beta exchange traded fund launched on 06/16/2006.
DFJ EWJ DXJ SBHGF 8473 SZHFF
The 2018 World Cup is starting today in Russia, with the host nation taking on Saudi Arabia. The biggest sporting event on planet will heat up over this month, with the champion being crowned on Jul 15, at the Luzhniki Stadium in Moscow. The mega football event would drive economic growth across continents, especially in industrial spaces such as media, advertising, restaurants, hotels and airlines.
After heightened political rhetoric, U.S. president Trump pulled out of the scheduled June meeting with North Korea’s Kim Jong Un. Strained relations between the United States and North Korea have been dominating the headlines for long. Late Tuesday, Trump commented that a planned historic meeting between the United States and North Korea may not take place if Pyongyang fails to comply with certain conditions (read: Quality ETFs in Focus on Dovish Fed).
DUKH AAXJ EWJ EWY O87 DUK XAR GLD
Adding fuel to the ongoing trade tensions, the Trump administration has initiated a national security investigation into auto imports that may result in fresh tariffs. And U.S. President Donald Trump’s urging that any deal would need “a different structure” has stirred global trade worries all over again.
EWC EWJ TM EWG TYT TOYOF CARZ MGA GM.WS.A GM.WS.B MG GM.WS.C 7203 GM GM.WSB TLRD
Asian economies have begun the year with continued solid - and in some cases robust - performance. Yet, the major Asian stock markets have diverged, with some significantly outperforming and others underperforming. In this note, we focus on Japan, China, and India.
AAXJ ACWX EWJ MCHI
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to EWJ / iShares MSCI Japan ETF on message board site Silicon Investor.
|EWJ : ISHARES MSCI JAPAN INDEX FD (AMEX)||iShares - EWJ, EWW, EWY, EWZ, etc.|
as of ET